<DOC>
	<DOCNO>NCT00333008</DOCNO>
	<brief_summary>The purpose study evaluate feasibility tolerability deliver full dose , time schedule dose-dense CDOP-R ( cyclophosphamide , doxil , vincristine , prednisone , rituximab ) NHL .</brief_summary>
	<brief_title>A Dose Study Doxil Dose Dense , 14 Day CDOP/Rituximab Regimen Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma ( NHL ) &gt; 60 Years With Compromised Cardiac Status .</brief_title>
	<detailed_description>Diffuse large B-cell lymphoma ( DLBCL ) frequent type non-Hodgkin 's lymphoma half patient age 60 year . Elderly patient cancer define American Society Clinical Oncology `` special population '' due disease characteristic , additional health problem , need aggressive supportive care strategy reduce morbidity mortality . The combination cyclophosphamide , doxorubicin , vincristine , prednisone ( CHOP ) remain standard therapy treatment DLBCL , elderly patient tend tolerate CHOP therapy less compare young patient . Cardiac toxicity , well decrease blood count , common side effect elderly population . For reason , many doctor reluctant use standard combination dose chemotherapy elderly fear increase morbidity . DLBCL elderly also somewhat unique elderly patient appear aggressive disease poor overall outcome . In order maximize tolerability treatment thus potentially enhance overall treatment success population , necessary look alternative treatment . This clinical trial base currently accept standard NHL therapy ( CHOP-Rituximab ) Doxil substitute Adriamycin . Growth factor use support acceptable blood count . Chemotherapy regimens include rituximab gold standard treatment DLBCL . If indeed , deliver full dose chemotherapy without treatment delay lead high remission cure rate , offer significant proportion NHL patient elderly chance cure rather provide treatment comfort measure preserve quality life .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>60 year old old 18 year old old significant/potential cardiac morbidity Diagnosis diffuse large B cell lymphoma , Ann Arbor stage IIV , International Prognostic Index ( IPI ) score . Previously untreated New York Heart Association ( NYHA ) classification Class III good Baseline ejection fraction ( EF ) &gt; 25 % Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 03 Unless attributable NHL : absolute neutrophil count ( ANC ) &gt; 1500/uL , platelet &gt; 100,000/uL ; hemoglobin &gt; 9.0 g/dl Bilirubin &lt; 1.5 mg/dL ( unless relate lymphoma ) Hepatic : transaminase &lt; 2.5 x upper limit normal ( ULN ) ( unless relate lymphoma ) Creatinine &lt; 2.5 mg/dl ( unless relate lymphoma ) No HIV+ individual No primary central nervous system ( CNS ) lymphoma No pregnant lactate woman No serious active infection History prior malignancy within last 5 year subject 's original cancer diagnosis list inclusion criterion exception curatively treat basal cell carcinoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Diffuse Large B Cell Lymphoma</keyword>
	<keyword>CDOP</keyword>
	<keyword>Dose Dense</keyword>
	<keyword>Anne Arbor Stage I-IV</keyword>
	<keyword>Any IPI score</keyword>
</DOC>